Skip to main content

Main menu

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Analysis

Policy alternatives for treatments for rare diseases

Abbas H. Panju and Chaim M. Bell
CMAJ November 23, 2010 182 (17) E787-E792; DOI: https://doi.org/10.1503/cmaj.081429
Abbas H. Panju
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chaim M. Bell
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF
Loading
Submit a Response to This Article
Compose Response

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
References
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'. Minimum 7 characters.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'. Minimum 12 characters.
Your organization, institution's or residential address.
Statement of Competing Interests

Vertical Tabs

Jump to comment:

  • PNH Prevalence
    Nadeem Chaudhry
    Posted on: 18 August 2010
  • Posted on: (18 August 2010)
    PNH Prevalence
    • Nadeem Chaudhry, Ann Arbor, USA

    Agreeably, we need a Canadian policy for treating rare diseases. Most developed nations have adopted such policies by defining criteria for rare diseases.

    Canadian prevalence of 2000 PNH patients is significantly high as stated.

    Currently, no epidemiological studies exist that clearly establish the incidence and prevalence of PNH in Canada. The most recent publication on PNH prevalence and incidence is...

    Show More

    Agreeably, we need a Canadian policy for treating rare diseases. Most developed nations have adopted such policies by defining criteria for rare diseases.

    Canadian prevalence of 2000 PNH patients is significantly high as stated.

    Currently, no epidemiological studies exist that clearly establish the incidence and prevalence of PNH in Canada. The most recent publication on PNH prevalence and incidence is a UK study published in 2006. The study identified all PNH patients by flow cytometry in a population of 3.7 million.1 Based on incidence and survival estimates, the study found the prevalence of patients with a PNH clone in this population to be 15.9/million. Patients with PNH who exhibit evidence of hemolysis are at the highest risk to suffer from the debilitating and life-threatening complications of PNH. While patients with lower clone sizes are generally less likely to exhibit evidence of hemolysis,2 there will be specific patients in this group who are important exceptions since they will be at higher risk for the severe complications of PNH and demonstrate hemolysis. Enriching the population for patients with clone sizes of 10% or greater (43% of all PNH patients and who are hemolytic (82.5% of all PNH patients) provides an estimate that 35% of all PNH patients, or approximately 5.6 patients/million population, are at highest risk for the severe and life-threatening complications of PNH.

    References 1. Hill A, Platts PJ, Smith A, et al. The incidence and prevalence of PNH and survival of patients in Yorkshire. Haematologica 2007;92 (suppl 2): abstr 0067. 2. Parker C, Omine M, Richards S, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood 2005;106:3699-709.

    Conflict of Interest:

    None declared

    Show Less
    Competing Interests: None declared.
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 182 (17)
CMAJ
Vol. 182, Issue 17
23 Nov 2010
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Policy alternatives for treatments for rare diseases
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Policy alternatives for treatments for rare diseases
Abbas H. Panju, Chaim M. Bell
CMAJ Nov 2010, 182 (17) E787-E792; DOI: 10.1503/cmaj.081429

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Policy alternatives for treatments for rare diseases
Abbas H. Panju, Chaim M. Bell
CMAJ Nov 2010, 182 (17) E787-E792; DOI: 10.1503/cmaj.081429
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Current state
    • Long-term alternatives
    • Knowledge gaps and future direction
    • Challenges to implementation
    • Conclusion
    • Footnotes
    • REFERENCES
  • Figures & Tables
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Managing conflicts of interest in the development of health guidelines
  • COVID-19 in long-term care homes in Ontario and British Columbia
  • Canadian federal–provincial/territorial funding of universal health care: fraught history, uncertain future
Show more Analysis

Similar Articles

Collections

  • Topics
    • Health policy
    • Canadian government

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions

Copyright 2021, Joule Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

Powered by HighWire